Mitsubishi Tanabe aims high as it eyes shift to new products and markets
This article was originally published in Scrip
Executive Summary
Despite falling far short of the goals of its last mid-term business programme, Japan's Mitsubishi Tanabe Pharma (MTP) has unveiled an ambitious new five-year management plan under which it is aiming for group operating profit of ¥100 billion ($1.30 billion) on net sales of ¥500 billion.